NEWSROOM
Press Releases by Agendia
News
Press Releases
Agendia to Present New FLEX Study Data at ASBrS 2026 Confirming the Consistent Performance of MammaPrint + BluePrint Across Diverse Racial Groups in Genomically Basal-Type Breast Cancer
Multivariate analyses reveal that pathologic complete response is associated with transcriptomic differences and chemotherapy type, rather than self-reported race IRVINE, Calif., and AMSTERDAM, May 1, 2026 — Agendia®, Inc., a leader in precision oncology Read More
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress
Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics IRVINE, Calif. & AMSTERDAM--Agendia®, Inc., a leader in precision oncology for breast cancer, Read More
Genomic Profiling with MammaPrint ® + BluePrint ® Identifies Aggressive Tumor Subtypes Driving Racial Survival Disparities in HR+/HER2– Early-Stage Breast Cancer
Multicenter study of over 1000 females with breast cancer, published in npj Breast Cancer, finds that genomic risk and molecular subtype, and not race, drives differential survival outcomes IRVINE, Calif., and AMSTERDAM — March Read More
Agendia Announces NCCN Guideline Update Recognizing MammaPrint to Guide Personalized Anthracycline Use in HR+/HER2- Early‑Stage Breast Cancer
Agendia Announces NCCN Guideline Update Recognizing MammaPrint to Guide Personalized Anthracycline Use in HR+/HER2- Early‑Stage Breast Cancer Update based on real-world evidence from the FLEX Study presented at the 2025 San Antonio Breast Cancer Read More
Agendia to Showcase MammaPrint and BluePrint Utility in Guiding Anthracycline Therapy at the 2025 San Antonio Breast Cancer Symposium
Four additional poster presentations from the ongoing real-world FLEX Study highlight the value of real-world data in personalizing chemotherapy decisions and improving outcomes in early-stage breast cancer IRVINE, Calif., and AMSTERDAM — November 25, Read More
Agendia Announces Publication in JNCI Cancer Spectrum Demonstrating that MammaPrint® Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer Using Real-World Evidence from the FLEX Study
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – August 12, 2025 – Agendia, Inc., a leader in innovative genomic testing for breast cancer, today announced the publication of new findings in JNCI Cancer Spectrum validating Read More
Agendia to Reveal Novel Breast Cancer Outcome Data Identifying Genomic Risk and Treatment Disparities Among Diverse Patient Population at 2025 ASCO Annual Meeting
FLEX Study Highlights Clinical Utility of MammaPrint® and BluePrint® in Diverse Patient Populations Across Breast Cancer Subtypes IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – May 27, 2025 – Agendia®, Inc., a leader in precision Read More
